Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed EBITDA Margin for 4 consecutive years, with 440356600.0% as the latest value for Q4 2023.

  • Quarterly EBITDA Margin fell 44034978036.0% to 440356600.0% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 2006393700.0% through Sep 2024, down 200638765523.0% year-over-year, with the annual reading at 7711.98% for FY2023, 697419.0% up from the prior year.
  • EBITDA Margin for Q4 2023 was 440356600.0% at Inhibikase Therapeutics, down from 5773.14% in the prior quarter.
  • The five-year high for EBITDA Margin was 186.56% in Q1 2021, with the low at 440356600.0% in Q4 2023.
  • Average EBITDA Margin over 4 years is 27549232.05%, with a median of 5440.26% recorded in 2023.
  • The sharpest move saw EBITDA Margin skyrocketed 25251477bps in 2022, then tumbled 2000000000bps in 2023.
  • Over 4 years, EBITDA Margin stood at 704.66% in 2020, then crashed by -36703bps to 259334.41% in 2021, then skyrocketed by 97bps to 6819.64% in 2022, then plummeted by -6457080bps to 440356600.0% in 2023.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 440356600.0%, 5773.14%, and 5107.38% for Q4 2023, Q3 2023, and Q2 2023 respectively.